Asana Biosciences Announces Appointment Of Louis Denis, M.D. As Chief Medical Officer

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Asana BioSciences, LLC, a clinical-stage biopharmaceutical company focused on the discovery and development of targeted anticancer therapies, today announced the appointment of Louis Denis, M.D., as its chief medical officer.

"I look forward to working with the Asana team and its scientific advisory board to advance the company's broad portfolio of differentiated targeted therapies to help address major unmet medical needs."

Dr. Denis is a medical oncologist with more than 20 years of academic and industry experience in clinical cancer drug development. He will be responsible for the overall strategic direction and medical oversight of the clinical development of Asana's novel product candidates. Prior to joining Asana, Dr. Denis held strategic and leadership positions in clinical development and medical affairs at Pfizer and, more recently, at Boehringer-Ingelheim, where he headed the US medical team for pipeline candidates and strategic partnerships. In his roles, he led and contributed to the clinical development of multiple product candidates, including the ErbB family blocker afatinib.

"We are extremely pleased with the addition of Dr. Denis, a highly experienced physician and scientist, to our team. It represents a significant step in our evolution as an oncology-focused clinical development company," said Sandeep Gupta, Ph.D., president and chief executive officer of Asana BioSciences.

Dr. Denis earned his medical degree from the Vrije Universiteit Brussels, Belgium. He completed his postdoctoral fellowships in internal medicine and medical oncology at Middelheim Hospital in Antwerp, Belgium, the Rotterdam Cancer Institute in the Netherlands, and the Cancer Therapy and Research Center in San Antonio, Texas. Dr. Denis is a co-inventor on multiple patents and co-authored over 30 scientific publications and presentations on cancer clinical research.

"I am delighted to join Asana at this transformative time for the company," said Dr. Denis. "I look forward to working with the Asana team and its scientific advisory board to advance the company's broad portfolio of differentiated targeted therapies to help address major unmet medical needs."

About Asana BioSciences, LLC

Asana BioSciences, LLC, an independent member of the Amneal Alliance of Companies, is a research and development company based in Bridgewater, NJ specializing in the discovery and development of new chemical and biological entities. Asana's portfolio consists of multiple early-stage drug discovery and development candidates in oncology and other indications. Asana's lead molecules ASN001 (CYP17 inhibitor for prostate cancer) and ASN002 (dual SYK-JAK inhibitor for non-Hodgkin's lymphoma and solid tumors) are currently in Phase I/II clinical studies in the US. For more information, please visit www.asanabiosciences.com.

Contacts

Asana BioSciences, LLC
Sandeep Gupta, Ph.D.
President and CEO
908-698-0848
[email protected]
www.asanabiosciences.com

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.